Levamlodipine besylate tablets

A technology of levamlodipine besylate and levo-amlodipine besylate, which is applied in the field of levamlodipine besylate tablets, can solve the problems of complex process, increase of impurities, and decrease of hygroscopicity, and achieve low impurity content and complete dissolution , the effect of stable quality

Active Publication Date: 2012-09-19
HEBEI RENHE YIKANG PHARMA
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Other patents may use inclusion methods to increase the stability of raw materials, but the process is complex, and they will also be in contact with water during the preparation process and heated during the drying process, which will inevitably increase impurities; or use the method of tablet film coating, Reduce its hygroscopicity and increase the stability during storage, but it adopts wet granulat...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Levamlodipine besylate tablets
  • Levamlodipine besylate tablets
  • Levamlodipine besylate tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～3

[0018] Embodiment 1~3 Levoamlodipine besylate tablet

[0019] Example

[0020] Preparation process: Mix the prescribed amount of levamlodipine besylate and pregelatinized starch, then add other ingredients, mix evenly, and press into tablets to obtain the product.

experiment example 1

[0021] Experimental Example 1 Stability study under high temperature conditions (60°C, without packaging)

[0022] The levamlodipine besylate sheet that embodiment 1~3 makes is detected by national standard WS1-(X-020)-2002Z, and compares with reference drug 1-3, and the result is as follows:

[0023]

[0024] *Comparative sample 1: prepared according to Example 1 of ZL201010134110.9 (the same below).

[0025] **Comparative drug 2: prepared according to Example 1 of CN200910186862.7 (the same below).

[0026] ***Comparative drug 3: prepared according to Example 1 of ZL200910147904.6 (the same below).

experiment example 2

[0027] Experimental Example 2 Stability study under high humidity conditions (25°C, RH92.5%, no packaging)

[0028] The levamlodipine besylate sheet that embodiment 1~3 makes is detected by national standard WS1-(X-020)-2002Z, and compares with reference drug 1-3, and the result is as follows:

[0029]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides levamlodipine besylate tablets. The levamlodipine besylate tablets have the characteristics of high stability, low impurity content, complete dissolution and the like.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a levamlodipine besylate tablet. Background technique [0002] Levoamlodipine besylate, namely (-) 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro -6-Methyl-3,5-pyridinedicarboxylate benzenesulfonate is a calcium channel blocker, which blocks extracellular calcium ions from cardiac muscle and vascular smooth muscle from entering cells through the calcium channel (slow channel) of the cell membrane, Direct relaxation of vascular smooth muscle, has antihypertensive effect. The mechanism of action of this product for relieving angina pectoris has not been fully determined, but it can reduce myocardial ischemia through the following effects: expand peripheral arterioles, reduce peripheral resistance (afterload), thereby reducing myocardial energy consumption and oxygen demand; normal expansion and ischemia The coronary arteries and coronary arterioles in the region i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/4422A61K47/38A61P9/12
Inventor 李春英
Owner HEBEI RENHE YIKANG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap